Sector Expert: Jeff Cohen

Ladenburg Thalmann

Image: Jeff Cohen

Jeffrey Cohen, director, equity research with Ladenburg Thalmann & Co. Inc., has more than 20 years of professional experience in the worldwide financial markets, working with such companies as Cantor Fitzgerald, the American Stock Exchange (NYSE Euronext) and Sanwa Bank. For the past 13 years, Cohen has been actively involved in direct research, analysis and marketing pertaining to the growing $2.7T U.S. healthcare sector, including detailed fundamental and financial analysis specific to the development, marketing, delivery and commercialization of medical technologies, therapeutics and various other healthcare solutions. During the past seven years, Cohen has developed, published and presented detailed fundamental analytical reports and financial models for more than 34 publicly traded and privately held medical technology, healthcare service and biotechnology companies with more than $14B in aggregate market capitalization. Cohen is an engineer by early training and education (BSE University of Pennsylvania), including several years of experience planning, designing and implementing complex fixed-rail automated transportation systems. He also holds a master's degree in business administration and various FINRA licenses.



Recent Interviews

Hidden Finds in Regenerative and Medical Technology: Jeff Cohen (9/12/13)

Ladenburg Thalmann & Co. Inc.'s Jeff Cohen regularly explores the frontiers of regenerative and medical technology looking for solid investment opportunities. In this interview with The Life Sciences Report, Cohen reveals promising finds in one of the world's fastest-growing business sectors. From robotics to skin grafts, Cohen knows his science and his market.

Recent Quotes

"VIVE's commercial activities continue to gain traction in a variety of worldwide markets with a current base of 162 systems."

— Jeff Cohen, Ladenburg Thalmann (11/14/16)
more >

— Jeff Cohen, Ladenburg Thalmann (10/7/16)
more >

"VIVE's Three human studies have been performed with extremely encouraging results."

— Jeff Cohen, Ladenburg Thalmann (9/20/16)
more >

"We would be buyers of TRX at current levels."

— Jeff Cohen, Ladenburg Thalmann (8/12/14)
more >

"We are initiating coverage on BLFS with a Buy rating."

— Jeff Cohen, Ladenburg Thalmann (7/23/14)
more >

"TBUFF placed 37.3M units for gross proceeds of CA$26.1M."

— Jeff Cohen, Ladenburg Thalmann (6/26/14)
more >

"We anticipate that TBUFF will generate positive EBITDA during FY/15."

— Jeff Cohen, Ladenburg Thalmann (5/27/14)
more >

"TBUFF has exclusively licensed Bilastine for the Canadian market."

— Jeff Cohen, Ladenburg Thalmann (5/16/14)
more >



Due to permission requirements, not all quotes are shown.